Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesGlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT
GlaxoSmithKline, 10/06/09
GlaxoSmithKline announced that the United States Food and Drug Administration’s Oncologic Drugs Advisory Committee voted unanimously in support of the approval of VOTRIENT. Specifically, the panel voted that the benefit–to–risk profile is acceptable for patients with advanced renal cell carcinoma. Pazopanib is an investigational, oral treatment for patients with advanced RCC.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections
Sanofi-aventis, 12/17/09
Telmisartan/amlodipine: approved for high blood pressure
Formulary , 12/16/09
Sponsor
Article Search
Sponsor
Sponsor